CV Sciences, Inc. (OTCQB:CVSI) reported financial results for the quarter ended September 30, 2026, including revenue of $3.0 million, a gross margin of 50.0% and positive adjusted EBITDA of $32,000. The company also reported lower operating expenses and continued regulatory monitoring related to hemp-derived cannabinoid products.
Third-quarter revenue was $3.0 million, compared with $3.3 million in the third quarter of 2025 and $3.0 million in the second quarter of 2026. CV Sciences said the year-on-year decline reflected lower sales volume linked to restrictive regulations at the federal level and in certain states, along with decreases in average sales prices.
The number of units sold fell by 4.7% compared with the third quarter of 2025. Gross margin was 50.0%, versus 48.5% in the prior-year quarter and 48.6% in the second quarter of 2026.
Operating expenses were $1.6 million, down from $1.8 million in the third quarter of 2025 and $1.7 million in the second quarter of 2026, excluding the benefit from the gain on legal settlement. The company recorded operating income of $0.4 million, compared with an operating loss of $0.3 million in the third quarter of 2025. CV Sciences attributed most of the improvement to a $0.5 million gain on legal settlement and lower operating expenses.
Adjusted EBITDA, which CV Sciences identifies as a non-GAAP measure, was positive at $32,000. The company reported adjusted EBITDA losses of $118,000 in the third quarter of 2025 and $132,000 in the second quarter of 2026.
CV Sciences reported a cash balance of $0.3 million at quarter and year end. Working capital was $0.7 million at quarter end, compared with $0.1 million at year end.
Products launched since January 1, 2023 accounted for 48% of third-quarter net revenue. The company said it launched 53 new products during that period.
During the quarter, CV Sciences expanded its +PlusHLTH™ portfolio with personalised wellness solutions designed to support healthy ageing. The company also continued monitoring potential updates to the implementation of restrictive federal provisions for hemp-derived cannabinoid products, which are currently scheduled to be in effect on December 11, 2026.
Joseph Dowling, Chief Executive Officer of CV Sciences, said the company remained focused on its established brands, broader science-based wellness categories, disciplined capital allocation and strategic opportunities. He also referred to ongoing regulatory challenges and pressure on revenue.
CV Sciences develops hemp extracts and other science-backed, natural ingredients and products. Its brands include +PlusCBD™, +PlusHLTH™ and Cultured Foods™, and the company also owns Elevated Softgels. Its products are sold through B2B and B2C channels.
The company scheduled a conference call and webcast for November 12, 2026, at 4:30 pm EDT/1:30 pm PDT to discuss the results. A telephone replay was scheduled to become available approximately three hours after the call concluded and remain available through Thursday, November 26, 2026.
CV Sciences, Inc. announced its financial results for the quarter ended September 30, 2026. The announcement also covered recent operating developments, regulatory monitoring and an expanded +PlusHLTH™ portfolio.
CV Sciences, Inc. generated revenue of $3.0 million in the third quarter of 2026. This compared with $3.3 million in the third quarter of 2025 and $3.0 million in the second quarter of 2026.
CV Sciences, Inc. reported a gross margin of 50.0% for the third quarter of 2026. The company reported 48.5% for the third quarter of 2025 and 48.6% for the second quarter of 2026.
CV Sciences, Inc. reduced operating expenses to $1.6 million in the third quarter of 2026, compared with $1.8 million in the third quarter of 2025. Operating expenses were also down from $1.7 million in the second quarter of 2026, excluding the benefit from the gain on legal settlement.
CV Sciences, Inc. reported positive adjusted EBITDA of $32,000 for the third quarter of 2026, compared with adjusted EBITDA losses of $118,000 in the third quarter of 2025 and $132,000 in the second quarter of 2026. The company defines adjusted EBITDA as a non-GAAP measure and says its adjustments include certain non-cash expenses and other items.
CV Sciences, Inc. reported a cash balance of $0.3 million at quarter and year end, and working capital of $0.7 million at quarter end. The company said working capital had improved from $0.1 million at year end.
CV Sciences, Inc. said the revenue decline was driven by lower sales volume resulting from restrictive regulations at the federal level and in certain states. The total number of units sold decreased by 4.7% compared with the third quarter of 2025, and the company also reported decreases in average sales prices.
CV Sciences, Inc. generated operating income of $0.4 million in the third quarter of 2026, compared with an operating loss of $0.3 million in the third quarter of 2025. The company said the improvement was mostly due to a $0.5 million gain on legal settlement and reductions in operating expenses.
Products launched since January 1, 2023 accounted for 48% of CV Sciences, Inc.'s third-quarter 2026 net revenue. The company said it launched 53 new products during that period.
CV Sciences, Inc. expanded its +PlusHLTH™ portfolio with personalised wellness solutions designed to support healthy ageing. The company said this formed part of its product innovation and diversification strategy.
CV Sciences, Inc. said it was continuing to monitor potential updates to the implementation of restrictive federal provisions for hemp-derived cannabinoid products. Those provisions are currently scheduled to be in effect on December 11, 2026.
Joseph Dowling, Chief Executive Officer of CV Sciences, said the company remains focused on strengthening its established brands, expanding its presence in broader science-based wellness categories, maintaining disciplined capital allocation and pursuing strategic opportunities that support sustainable growth and long-term shareholder value. He also described ongoing regulatory challenges and pressure on revenue.
CV Sciences, Inc. is a consumer wellness company specialising in hemp extracts and other science-backed, natural ingredients and products. Its products are sold through sales channels ranging from B2B to B2C, and its brands include +PlusCBD™, +PlusHLTH™ and Cultured Foods™, while it also owns Elevated Softgels.
CV Sciences, Inc. is identified in the announcement as trading on the OTCQB under the ticker symbol OTCQB:CVSI.
CV Sciences, Inc. said it would host a conference call and webcast on November 12, 2026, at 4:30 pm EDT/1:30 pm PDT to discuss the results. The webcast was made available through the company's Investor Relations section and a telephone replay was scheduled to be available approximately three hours after the call concluded through Thursday, November 26, 2026.